| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J9015 | Aldesleukin | Proleukin | Per single vial (1 vial = 22 million IU) | Immunotherapy | Cytokine | Interleukin-2 | No | 1992 | Oct 1, 1996 | In Use | ||
| NA | Gardasil-9 | Human papillomavirus vaccine | Ancillary Therapy | Protective Agent | HPV Vaccine | No | 2016 | In Use | ||||
| NA | Chlorotrianisene | Anisene | 12 mg | Hormonal Therapy | Estrogen | Yes | 1992 | 1997 | In Use | |||
| NA | Sotorasib | Lumakras | Multiple | Chemotherapy | RAS Inhibitor | KRASG12C | Yes | 2021 | In Use | |||
| J9380 | Teclistamab cqyv | Tecvayli | 0.5mg | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | No | 2022 | Jul 11, 2023 | In Use | ||
| NA | Anastrozole | Arimidex | 0.5 mg | Hormonal Therapy | Aromatase Inhibitor | Yes | 1995 | In Use | ||||
| NA | Uracil Mustard | Uramustine | unspecified | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1962 | 1999 | No Longer Used | ||
| J9003 | Leuprolide | Camcevi etm | 1mg | Hormonal Therapy | GnRH Agonist | No | 2022 | Mar 18, 2026 | In Use | |||
| C9449 | Blinatumomab | Blincyto | 1 mcg | Immunotherapy | Monoclonal Antibody | CD3 (T cells) and CD19 (B cells) | No | 2014 | Apr 1, 2015 | In Use | ||
| NA | Dutasteride | Avodart | 0.5mg | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Yes | 2002 | In Use | |||
| J0885 | Epoetin Alfa | Epogen, Procrit | 1000 units | Ancillary Therapy | Erythropoiesis-Stimulating Agent | No | 1989 | Jan 1, 2006 | In Use | |||
| J2354 | octreotide | sandostatin | 25 mcg | Hormonal Therapy | Somatostatin Analog | No | 1998 | Jan 1, 2004 | In Use | |||
| NA | Thalidomide | Thalomid | 50 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 1998 | In Use | |||
| NA | Erlotinib | Tarceva | 150 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2004 | In Use | |||
| J8705 | Topotecan | Hycamtin | 0.25 mg | Chemotherapy | Topoisomerase I Inhibitor | Campothecin Analogs | Yes | 1996 | Jan 1, 2009 | In Use | ||
| Asciminib | Scemblix | 20mg,40mg | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Yes | 2021 | In Use | ||||
| NA | Aprepitant | Emend | 40 mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Yes | 2003 | In Use | |||
| NA | Umbralisib | Ukoniq | 260.2mg | Chemotherapy | Enzyme Inhibitor | PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 | Yes | 2021 | In Use | |||
| J9022 | Atezolizumab | Tecentriq | 10mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2016 | Jan 1, 2018 | In Use | ||
| J2860 | Siltuximab | Sylvant | 10 mg | Immunotherapy | Monoclonal Antibody | IL-6 | No | 2014 | Jan 1, 2016 | In Use | ||
| Q5126 | Bevacizumab-maly | Alymsys | 10mg | Immunotherapy | Monoclonal Antibody | VEGF | No | 2022 | Nov 28, 2022 | In Use | ||
| J0207 | Amifostine | Ethyol | 500 mg | Ancillary Therapy | Chemoprotective | Detoxifying Agent | No | 1995 | Jan 1, 1998 | In Use | ||
| J9030 | Bacillus calmette-guerin | BCG Vaccine, Tice BCG | 1mg | Immunotherapy | Biological Response Modifier | Live Vaccine | No | 1990 | Jul 1, 2019 | In Use | ||
| J9065 | Cladribine | Cladribine | per 1 mg | Chemotherapy | Antimetabolite | Purine Analog | No | 1993 | Jan 1, 1995 | In Use | ||
| NA | Estradiol | Estrace | 0.5mg | Hormonal Therapy | Estrogen | Yes | 1998 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home